Table 1 Baseline characteristics of studied groups
Stroke patients D1 N = 52 | Disease controls N = 34 | p value | |
|---|---|---|---|
Age, years | 69 (± 12) | 68 (± 13) | 0.66 |
BMI (kg/m2) | 25.4 (23.6–28.4) | 27.0 (25.1–31.1) | 0.37 |
Females, n (%) | 25 (48) | 13 (38) | 0.39 |
Hypertension, n (%) | 42 (81) | 30 (88) | 0.56 |
Diabetes, n (%) | 10 (19) | 6 (18) | > 0.99 |
Ischemic heart disease, n (%) | 19 (37) | 14 (41) | 0.82 |
Atrial fibrillation, n (%) | 20 (39) | 3 (9) | < 0.01 |
Hyperlipidemia (%) | 16 (31) | 12 (35) | 0.81 |
Smoking, n (%) | 18 (35) | 7 (21) | 0.23 |
Treatment, n (%) | |||
Thrombolysis | 16 (31) | – | |
Antiplatelet drugs | 45 (87) | 34 (100) | 0.72 |
Anticoagulant | 7 (14) | 0 | 0.04 |
ACEI | 20 (39) | 17 (50) | 0.37 |
Diuretics | 23 (44) | 12 (35) | 0.51 |
CCB | 22 (42) | 17 (50) | 0.51 |
β-blockers | 9 (17) | 8 (24) | 0.58 |
ARB | 7 (14) | 1 (3) | 0.14 |
Statins | 14 (27) | 15 (44) | 0.11 |
Hypoglycemics | 8 (15) | 4 (13) | 0.78 |
Insulin | 3 (6) | 3 (9) | 0.68 |
Stroke etiology (TOAST classification), n (%) | |||
LVD | 13 (25) | – | – |
SVD | 12 (23) | – | – |
CE | 22 (42) | – | – |
OE | 5 (10) | – | – |
UE | 0 | – | – |
Stroke location, n (%) | |||
TACI | 6 (12) | – | – |
PAC | 22 (42) | – | – |
POCI | 13 (27) | – | – |
LACI | 10 (8) | – | – |
Stroke lesion volume, mL | |||
Day 1 | 2.1 (0.3–11.2) | – | – |
Day 90 | 1.0 (0.4–4.7) | – | – |